Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Curr Drug Metab. 2012 Oct;13(8):1110-8. doi: 10.2174/138920012802850100.
Oral administration remains the most preferred route for the treatment of many diseases due to its convenience and adaptability. However, the presystemic metabolism may be an important barrier that prevents lipophilic drugs from achieving their pharmacological effects following oral delivery. Nano-based drug delivery system provides an effective strategy to reduce the presystemic metabolism and increase the systemic exposure of lipophilic drugs. In this review, we described the physiological factors affecting the presystemic metabolism of lipophilic drugs, intestinal transport of nanosystems, strategy of nanosystems to avoid the presystemic metabolism, and the current application of various oral nanosystems including lipid and polymeric nanocarriers. The nano-based drug delivery system has a lot of potential for reducing the presystemic metabolism and enhancing the bioavailability of orally administrated lipophilic drugs.
口服给药因其方便性和适应性仍然是治疗许多疾病的首选途径。然而,药物的首过代谢可能是一个重要的障碍,阻止亲脂性药物在口服给药后发挥其药理作用。基于纳米的药物传递系统为减少亲脂性药物的首过代谢并增加其全身暴露提供了有效的策略。在这篇综述中,我们描述了影响亲脂性药物首过代谢的生理因素、纳米系统的肠道转运、纳米系统避免首过代谢的策略以及包括脂质和聚合物纳米载体在内的各种口服纳米系统的当前应用。基于纳米的药物传递系统在减少亲脂性药物的首过代谢和提高口服生物利用度方面具有很大的潜力。